EA201391136A1 - Лиофилизированные составы - Google Patents

Лиофилизированные составы

Info

Publication number
EA201391136A1
EA201391136A1 EA201391136A EA201391136A EA201391136A1 EA 201391136 A1 EA201391136 A1 EA 201391136A1 EA 201391136 A EA201391136 A EA 201391136A EA 201391136 A EA201391136 A EA 201391136A EA 201391136 A1 EA201391136 A1 EA 201391136A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lyophylized
compositions
liquid mixture
polypeptide
polypeptide composition
Prior art date
Application number
EA201391136A
Other languages
English (en)
Other versions
EA029972B1 (ru
Inventor
Джеймс Кранц
Джозеф Ринелла
Original Assignee
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГЛЭКСОСМИТКЛАЙН ЭлЭлСи filed Critical ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Publication of EA201391136A1 publication Critical patent/EA201391136A1/ru
Publication of EA029972B1 publication Critical patent/EA029972B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Abstract

Изобретение относится к способу получения полипептидной композиции, включающему объединение полипептида с добавкой летучего вещества с образованием жидкой смеси и лиофилизацию жидкой смеси с получением лиофилизированной полипептидной композиции.
EA201391136A 2011-02-09 2012-02-09 Способы получения полипептидных композиций EA029972B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161440918P 2011-02-09 2011-02-09
PCT/US2012/024452 WO2012109429A2 (en) 2011-02-09 2012-02-09 Lyophilized formulations

Publications (2)

Publication Number Publication Date
EA201391136A1 true EA201391136A1 (ru) 2014-05-30
EA029972B1 EA029972B1 (ru) 2018-06-29

Family

ID=46639199

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391136A EA029972B1 (ru) 2011-02-09 2012-02-09 Способы получения полипептидных композиций

Country Status (16)

Country Link
US (1) US10286037B2 (ru)
EP (1) EP2672986B1 (ru)
JP (1) JP6125436B2 (ru)
KR (1) KR20140044305A (ru)
CN (2) CN107837395A (ru)
AU (1) AU2012214419B2 (ru)
BR (1) BR112013020383A2 (ru)
CA (1) CA2827033A1 (ru)
DK (1) DK2672986T3 (ru)
EA (1) EA029972B1 (ru)
ES (1) ES2791690T3 (ru)
IL (1) IL227896B (ru)
MX (1) MX2013009280A (ru)
SG (1) SG192671A1 (ru)
WO (1) WO2012109429A2 (ru)
ZA (1) ZA201306118B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0910854A2 (pt) 2008-03-28 2015-10-06 Glaxosmithkline Llc métodos de tratamento
MX2016012447A (es) 2014-03-24 2017-01-06 Biogen Ma Inc Formulaciones de factor ix liofilizadas.
CN103920148B (zh) * 2014-04-24 2016-06-22 山东新华医疗器械股份有限公司 一种单克隆抗体制剂的冷冻干燥工艺
CN103966323A (zh) * 2014-04-25 2014-08-06 广州迪澳生物科技有限公司 可常温运输的干粉化恒温扩增检测试剂及其制备方法
US20170065707A1 (en) * 2014-05-06 2017-03-09 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable human papillomavirus formulations
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
BR112016030588A2 (pt) * 2014-06-25 2017-10-31 Glaxosmithkline Llc composições farmacêuticas
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
BR112018003741A2 (pt) 2015-08-24 2018-09-25 Glaxosmithkline Ip No 2 Ltd composições biofarmacêuticas
US20190119642A1 (en) 2016-03-15 2019-04-25 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CN107661288A (zh) * 2016-07-29 2018-02-06 江苏泰康生物医药有限公司 含有glp‑1 类似物融合蛋白的稳定液体制剂及其制备
EA201991207A1 (ru) * 2016-12-19 2019-12-30 Гленмарк Фармасьютикалс С.А. Новые агонисты tnfr и их применение
AU2017382281A1 (en) * 2016-12-22 2019-06-13 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
WO2018226339A1 (en) * 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
CN110747263B (zh) * 2019-11-12 2023-04-07 南京黎明生物制品有限公司 一种冻干添加剂及荧光pcr反应混合物干粉和制备方法
CN111165656A (zh) * 2020-01-09 2020-05-19 南京大学（溧水）生态环境研究院 一种黑水虻冻干粉高效制备方法
CN113081955B (zh) * 2020-01-09 2023-10-24 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的制剂
CN116643056A (zh) * 2022-02-15 2023-08-25 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
CN116159027A (zh) * 2022-12-29 2023-05-26 江苏诺泰澳赛诺生物制药股份有限公司 一种司美格鲁肽冻干药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US20030017169A1 (en) 2000-12-29 2003-01-23 Sidney Pestka Controlled release systems for polymers
CA2471363C (en) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
JP2009514900A (ja) 2005-11-04 2009-04-09 スミスクライン・ビーチャム・コーポレイション 血糖降下剤の投与方法
CN101404980A (zh) 2006-01-24 2009-04-08 耐百生物制药有限公司 大分子微球的制备技术
WO2008073458A2 (en) 2006-12-11 2008-06-19 Bracco Imaging S.P.A. Fibrin-binding peptides and conjugates thereof
CN101274096B (zh) * 2007-03-29 2011-04-27 上海万兴生物制药有限公司 一种稳定的巴曲酶药物组合物
KR101478779B1 (ko) 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
US8275057B2 (en) * 2008-12-19 2012-09-25 Intel Corporation Methods and systems to estimate channel frequency response in multi-carrier signals
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
RU2012108108A (ru) 2009-08-04 2013-09-10 Дженентек, Инк. Концентрированные полипептидные лекарственные формы с пониженной вязкостью
CN102018676B (zh) * 2010-12-21 2012-12-05 中山大学 一种水溶性药物纳米粒及其混悬型气雾剂的制备方法

Also Published As

Publication number Publication date
CA2827033A1 (en) 2012-08-16
US20140044717A1 (en) 2014-02-13
EP2672986A4 (en) 2015-12-30
ZA201306118B (en) 2014-04-30
IL227896A0 (en) 2013-09-30
ES2791690T3 (es) 2020-11-05
BR112013020383A2 (pt) 2017-06-13
MX2013009280A (es) 2013-09-06
AU2012214419B2 (en) 2015-12-24
WO2012109429A3 (en) 2012-10-18
KR20140044305A (ko) 2014-04-14
DK2672986T3 (da) 2020-06-08
JP6125436B2 (ja) 2017-05-10
IL227896B (en) 2018-12-31
EA029972B1 (ru) 2018-06-29
EP2672986B1 (en) 2020-03-18
EP2672986A2 (en) 2013-12-18
JP2014506578A (ja) 2014-03-17
US10286037B2 (en) 2019-05-14
AU2012214419A1 (en) 2013-08-29
CN103492407A (zh) 2014-01-01
CN107837395A (zh) 2018-03-27
WO2012109429A2 (en) 2012-08-16
SG192671A1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
EA201391136A1 (ru) Лиофилизированные составы
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EA201491644A1 (ru) Фармацевтические композиции
EA201391489A1 (ru) Композиции со сниженной вязкостью
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201890942A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201590887A1 (ru) Композиция
UA114289C2 (uk) Неводні концентровані суспензійні композиції зі зниженою в'язкістю на основі антитіл
GT201400111A (es) Triazolopiridinas sustituidas
EA201291117A1 (ru) Иммуногенные композиции и способы лечения неоплазии
EP3929217A3 (en) Specific sites for modifying antibodies to make immunoconjugates
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA202190619A1 (ru) Противовирусные соединения
IN2015DN03322A (ru)
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
UY35492A (es) Compuestos novedosos
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201390660A1 (ru) Модифицированные никотиновые соединения и связанные способы
EA201391488A1 (ru) Композиции со сниженной вязкостью
EA201490024A1 (ru) Наполненные силиконовые композиции, их получение и применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU